Establish a strong foundation for commercially successful therapies and advance from concept to candidate with Element's integrated discovery biology services.

Accelerate pre-clinical drug discovery with Element’s extensive offering of biochemical and cell-based assays. Our discovery biology services are built upon a foundation of deep expertise in biochemistry, signal transduction, and cell biology. Interested in discovery biology services? Request more information

Extensive biochemical assays

Leverage our portfolio of biochemical assays that includes >600 druggable protein targets, including kinases, proteases, phosphatases - and many other enzymes regulating cell survival and apoptosis, epigenetic and metabolic circuits, and protein homeostasis. Flexible assay formats range from HTS and high content profiling to sophisticated mechanism of action (MOA) studies.

In addition to extensive experience performing high throughput screening for broad kinase, epigenetic and protein homeostasis, new new biochemical and cell-based assays can be developed quickly using modern detection methods, including TR-FRET, FP, BRET, Flow-Cytometry, LC-MS/MS, and state-of-the-art compound delivery approaches (acoustic dispensing). New assays are tailored to meet your needs and fully validated with highly standardized procedures. Looking to talk about your discovery biology and biochemical assay needs? Get in touch with us today.

Comprehensive cell-based assays and bioassays

Our cell-based assays utilize a large in-house collection of stable cell lines as well as primary cells and whole human blood. We perform intracellular drug-target engagement assays, phosphoprotein accumulation, and protein degradation assays. Plus, we offer cytokine ELISA, cell proliferation, and multiplex flow cytometry assays. Want to know more? Start the conversation

The ÌÇÐÄlogoÃ×·ÆÍÃadvantage 

We're committed to helping you accelerate pre-clinical discovery with our systematic approach, aligning biochemical profiling and cell-based screening activities. So, let's talk about your goals and how we can make a difference.

Cell-based screening and profiling

  • Dose response studies
  • Drug combination studies

Development of new cell models

  • Generation of target-specific models

Cell-based assays in a wide variety of cell types

Advance discovery with our large collection of tumor cell types, including 120 cell lines. We can also produce stable cell lines expressing proteins of interest (lentiviral delivery). Cell-based assays include: 

Cytotoxicity assays

  • Cell viability/proliferation
  • Apoptosis/necrosis

Target engagement assays

  • NanoBRET TE assays with >100 available kinase targets
  • Kinase occupancy assays with Ibrutinib-Biotin as a probe
  • Proteasome occupancy assays with biotinylated PABP probe
  • BTK, EGFR, FGFR , CDK degradation assays (HTRF and Western)
  • MDM2 degradation assay (Western)
  • BCL6 degradation assay (Western)

Phospho-protein assays

  • HRTF based assays
  • Flow cytometry

Cytokine secretion ELISA assays

  • Typically performed in normal human peripheral blood cells (PBMCs) or in whole human blood 

Flow cytometry assays

In cell ELISA assays

Biochemical screening and profiling

  • HTS, fragment screening
  • Dose response studies, medium to high throughput screening
  • Selectivity profiling

Biochemical assay development

  • Protein sourcing characterization
  • Substrate identification
  • Assay validation
  • SOP preparation

Biochemical MoA studies

  • Kinetic studies (Ki, Kinact, residence time)
  • Dialysis and rapid dilution studies
  • Kinase activation cascades
  • Substrate competition studies

 

Our team of over 9,000 Engaged Experts in North America, Europe, The Middle East, Australia, Asia and Africa are ready to help you.